Synairgen raises £87m to bring Covid-19 treatment to market

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
ABBs-Block Trades

Synairgen raises £87m to bring Covid-19 treatment to market

Aidan Gregory
November 02, 2020 05:00 pm
Synairgen_2_PA_575_375
LUGANSK, UKRAINE - OCTOBER 30, 2020: The entrance to the 'red zone' at a standby facility for COVID-19 patients in serious condition opened at the Lugansk Republican Clinical Hospital. Alexander Reka/TASS | Alexander Reka/Tass/PA Images

UK biotech firm Synairgen has finished the second leg of an £87m capital increase to fund the next round of clinical trials of a treatment designed to alleviate the respiratory symptoms of Covid-19.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

EquityABBs-Block TradesUKEuropeEMEA
AG
Aidan Gregory
Gift this article